av-1959
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 27, 2023 (NCT05642429)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinImmunity, active
APP immunity, active
- Amyloid beta precursor like protein 1Immunity, active
APLP1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06831812 | Phase 1 | Jun 12, 2024 | Nuravax, Inc. |
| NCT05642429 | Phase 1 | Feb 27, 2023 | Clinartis, Institute for Molecular Medicine, National Institute on Aging (NIA) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clinartis | For profit | 1 | 0 | 1 | 2023 |
| Institute for Molecular Medicine | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2023 |
| Nuravax, Inc. | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1